Blood-based biomarkers for Alzheimer's disease and cognitive function from mid- to late life.

Xin WangKelly M BakulskiCarrie A Karvonen-GutierrezSung Kyun ParkDavid MorganRoger L AlbinHenry L Paulson

Published in: Alzheimer's & dementia : the journal of the Alzheimer's Association (2023)

This study investigates midlife serum AD biomarkers on longitudinal cognitive function changes in women. Mid-life serum AD biomarkers are associated with accelerated cognitive decline. A decrease in the Aβ42/40 ratio was associated with a faster decline in the DSB score. A higher p-tau181 concentration was associated with a faster decline in the SDMT score.

Keyphrases

cognitive decline
mild cognitive impairment
polycystic ovary syndrome
adipose tissue
cerebrospinal fluid
breast cancer risk